Key facts
- Aillis’s last known valuation is $125.2M (Apr 2025).
- It has raised $54.6M; the latest was Later Stage VC ($13.4M) in Apr 2025.
- Notable investors include J-Startup, Nissay Capital, Z Venture Capital, Pegasus Tech Ventures, Mirai Creation Capital — 27 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 27 names
- ·Watchlist + deal alerts for Aillis
- ·The full record, as it builds
Funding rounds
No funding rounds for Aillis are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aillis
Developer of an artificial intelligence-equipped pharyngoscopy system designed to diagnose infectious diseases from pharyngeal photographs. The company's platform utilizes a specialized camera to capture images of the pharynx and applies AI technology to analyze the images for signs of infection, enabling healthcare providers to diagnose illnesses efficiently and accurately.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2017
- Employees
- 100
- Website
- aillis.jp/
- Ownership
- Privately Held (backing)
Aillis doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aillis shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aillis in its N-PORT filings yet. We sweep new filings monthly.